echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The rare disease new drug "Vitolasheng Injection" is declared for listing, and it is planned to be reviewed first

    The rare disease new drug "Vitolasheng Injection" is declared for listing, and it is planned to be reviewed first

    • Last Update: 2021-08-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 9th, the CDE official website announced the latest announcement that it was planned to include Vitorasin injection into the priority review and approval.


    Source: CDE official website

    Duchenne muscular dystrophy (Duchenne muscular dystrophy, DMD) is the most common X-linked recessive hereditary muscular degeneration disease, the incidence in male newborns is about 1/3500.


    Vitorasheng injection is an antisense oligonucleotide drug jointly developed by Tigermed and Japan New Drug Co.


    In a phase II clinical trial (NCT02740972), 16 subjects were randomized to receive this product or placebo for 4 weeks, and then received 2 different doses (40 mg/kg, 80 mg/kg) of Vitor Open treatment for 20 weeks


    On March 25, 2020, Vittorase was approved for listing in Japan; on August 12, 2020, it was approved for listing in the United States.


    In May 2021, Vitorasen injection was applied for clinical application in China for the first time, and it was approved for clinical use on July 13


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.